I joined the Cancer Immunology Department at Genentech in 2017 after completing post-doctoral work at the University of Oxford, UK, where I studied the inflammatory processes that underlie inflammatory bowel disease and colorectal cancer. Prior to this, I trained in immune-oncology at the British Columbia Cancer Agency, with a focus on inflammation in breast cancer.
At Genentech, my team studies the complex mechanisms of communication that exist between immune and non-immune cells in tumors, with the goal of developing novel immunotherapies for cancer.
Nature Medicine 23: 579–89.
The immune system employs an astonishingly complex system of cell-to-cell communication that coordinates host protection against pathogens and cancer, while limiting inappropriate activities that could cause inflammatory pathology or autoimmunity. Cytokines are particularly critical for the proper functioning of this system, and thus constitute an exciting area for biomedical research and drug development.
With the ultimate goal of developing new approaches for cancer immunotherapy, my team explores the basic biology of cytokines in anti-tumor immunity, how we can inhibit the activity of cytokines that restrain protective anti-tumor immune responses, and how to augment beneficial cytokine pathways. We believe that by integrating such strategies with other immunotherapy approaches (such as immune checkpoint blockade or cellular therapies), we can unlock the full tumor-fighting potential of the immune system and bring significant benefit to patients with a wide range of cancers.